Graduate Studies Reports Access

Graduate Course Proposal Form Submission Detail - NGR6146
Tracking Number - 2820

Edit function not enabled for this course.

Current Status: Approved by SCNS - 2012-05-15
Campus: Tampa
Submission Type: New
Course Change Information (for course changes only):
Comments: for MS in Nursing; to GC 4/2/12; to USF Syst for conc 4/5/12; to GC 4/16/12; to SCNS 4/16/12; SCNS Appd eff 6/1/12. Mbr 6145 appd as 6146

Detail Information

  1. Date & Time Submitted: 2012-02-29
  2. Department: Nursing
  3. College: NR
  4. Budget Account Number: 620100020
  5. Contact Person: Dewel Lindsey
  6. Phone: 8133969978
  7. Email: jlindsey@health.usf.edu
  8. Prefix: NGR
  9. Number: 6146
  10. Full Title: Pathophysiology/Pharmacology for the Advanced Generalist Nurse
  11. Credit Hours: 4
  12. Section Type: C - Class Lecture (Primarily)
  13. Is the course title variable?: N
  14. Is a permit required for registration?: N
  15. Are the credit hours variable?: N
  16. Is this course repeatable?:
  17. If repeatable, how many times?: 0
  18. Abbreviated Title (30 characters maximum): Path/Pharm for Adv Gen Nurse
  19. Course Online?: O - Online (100% online)
  20. Percentage Online: 0
  21. Grading Option: R - Regular
  22. Prerequisites:
  23. Corequisites:
  24. Course Description: Course will focus on what is currently known about the pathophysiology of commonly seen diseases with updates in pharmacology. A case study approach will be used.

  25. Please briefly explain why it is necessary and/or desirable to add this course: Needed for accreditation
  26. What is the need or demand for this course? (Indicate if this course is part of a required sequence in the major.) What other programs would this course service? Required for advanced generalist nurse core
  27. Has this course been offered as Selected Topics/Experimental Topics course? If yes, how many times? No
  28. What qualifications for training and/or experience are necessary to teach this course? (List minimum qualifications for the instructor.) knowledge of pathophysiology and pharmacology
  29. Objectives: At the end of this course, the student will be able to:

    1. Discuss pathogenic mechanisms of selected disease processes (E1)

    2. Differentiate the etiological factors of selected disease processes and related pharmacological interventions across the lifespan (E1)

    3. Examine the physical presentation, nursing management, and research trends of selected clinical situations, using an enhanced understanding of physiology, homeostasis, nutrition, chemistry, and pharmacology in the critical thinking and decision-making involved (E1, 4)

    4. Plan management of care for selected clinical situations that reflects a clear understanding of the underlying principles (E1, 8)

    5. Apply pathophysiology and pharmacology principles to case study scenarios (E1, 8)

  30. Learning Outcomes: 1. In clinical situations, relate an understanding of the pathogenic and pharmacologic factors affecting life processes.

    2. Using a provided case study scenario incorporate knowledge of pathophysiology and provide rationale for pharmacologic interventions.

  31. Major Topics: 1. Introduction

    a. Current issues in pharmacology

    i. Influences changing practice

    1. Media

    2. Internet

    3. Alternative therapies

    i. Safety issues

    ii. FDA focus and initiatives

    b. Review of pathophysiology

    i. Inflammation/immunity

    ii. Stress reaction

    iii. Changes with aging

    c. Principles of teaching/learning

    2. Cell review

    a. Cell physiology

    b. The nucleus, genes, reproduction

    c. Advances in treating and altering cells including pharmacology of antibiotics, antivirals, antifungals, antineoplastics

    i. Cancer

    ii. Invaders

    1. Antibiotics

    2. Antifungals

    3. Inflammation and immunity

    a. Pain update

    i. Arthritis - treatment and management options, including pharmacology of opiods, NSAIDs and immune modulations

    b. Immune modulators

    c. Vaccinations

    i. Adult/pediatric – new guidelines and pharmacology of vaccines, immune

    ii. sera

    4. CNS

    a. Review of current thinking about the nervous system

    b. Pathophysiology and advances in the management, including pharmacology, of:

    i. Headache: (ergots, triptans, opiods, NSAIDs)

    ii. Parkinson’s disease (dopaminergics, anticholinergics, adjunct drugs)

    iii. Alzheimer’s disease (cholinergics, NMDA receptor agonist)

    iv. Smoking (nicotine, nicotine receptor agonist, antidepressants)

    v. Sleeping problems (sedative, hypnotics)

    vi. Psych issues (benzodiazepines, typical and atypical antipsychotics, SSRIs, mixed receptor antagonists)

    5. Endocrine disorders

    a. Review of current thinking about the endocrine system

    b. Pathophysiology and advances in management, including pharmacology of:

    i. Diabetes (insulin, sulfonylureas, alpha-glucosidase inhibitors, biguanide, DPP4 inhibitor, amylin, incretin mimetics, meglitinide, thiazolidines)

    ii. Thyroid review (replacement, blockers)

    iii. Hormone imbalance (estrogens, progesterones, testosterones, androgens)

    iv. Parathyroid and bone density (bisphosphonates, PTH, calcitonin)

    6. Cardiovascular

    a. Review of current thinking about the CV system and heart disease

    b. Pathophysiology and advances in management, including pharmacology, of:

    i. Hypertension (ACEIs, ARBs, renin blockers, adrenergic blockers, calcium channel blockers, thiazide diuretics)

    ii. Lipid abnormalities (HMG CoA inhibitors, fibrates, bile acid sequestrants, absorption inhibitors, fish oil)

    iii. CAD (nitrates, beta blockers, calcium channel blockers, nitraties, piperazineacetamide)

    iv. CHF (diuretics, cardiac glycosides, calcium channel blockers, adrenergic blockers, phosphodiesterase inhibitors, vasodilators, natriuretic peptide)

    7. Respiratory

    a. Review of current thinking about the respiratory system

    b. Pathophysiology and advances in management, including pharmacology, of:

    i. Allergy, seasonal rhinitis (decongestants, topical steroids, antihistamines, mucolytics_

    ii. Asthma (xanthines, sympathomimetics, inhaled steroids, leukotriene receptor antagonists)

    iii. COPD (xanthines, sympathomimetics, anticholinergics)

    8. GI

    a. Review of current thinking about the GI system and liver

    b. Pathophysiology and advances in the management of including pharmacology, of:

    i. Acid imbalance (antacids, histamine-2 inhibitors, proton pump inhibitors)

    ii. Mobility imbalance (laxatives, GI stimulants)

    iii. GI ulcers (histamine-2 inhibitors, proton pump inhibitors, prostaglandings, GI protectants)

    9. Renal/GU system

    a. Review of current thinking about the renal system, bladder

    b. Pathophysiology and advances in the management, including pharmacology, of:

    i. Renal failure

    ii. Diabetic nephropathy (ARBS,ACEIs)

    iii. UTIs (antibiotics, urine acidifiers, urinary tract analgesics, antispasmodics)

    iv. BPH (alpha blockers, androgen inhibitors)

    v. ED (prostaglandin phosphodiesterase inhibitors)

  32. Textbooks: Porth, C. M. & Matfin, G. (2010). Pathophysiology: Concepts of altered health states (8th

    ed.). Philadelphia, PA: Lippincott, Williams, and Wilkins.

    Karch, A. M. (2009). Focus on nursing pharmacology (5th ed.). Philadelphia, PA:

    Lippincott, Williams, and Wilkins.

  33. Course Readings, Online Resources, and Other Purchases:
  34. Student Expectations/Requirements and Grading Policy: Exams

    Papers

    Presentations

    Discussion

  35. Assignments, Exams and Tests: Exams

    Papers

    Presentations

    Discussion

  36. Attendance Policy: Course Attendance at First Class Meeting – Policy for Graduate Students: For structured courses, 6000 and above, the College/Campus Dean will set the first-day class attendance requirement. Check with the College for specific information. This policy is not applicable to courses in the following categories: Educational Outreach, Open University (TV), FEEDS Program, Community Experiential Learning (CEL), Cooperative Education Training, and courses that do not have regularly scheduled meeting days/times (such as, directed reading/research or study, individual research, thesis, dissertation, internship, practica, etc.). Students are responsible for dropping undesired courses in these categories by the 5th day of classes to avoid fee liability and academic penalty. (See USF Regulation – Registration - 4.0101,

    http://usfweb2.usf.edu/usfgc/ogc%20web/currentreg.htm)

    Attendance Policy for the Observance of Religious Days by Students: In accordance with Sections 1006.53 and 1001.74(10)(g) Florida Statutes and Board of Governors Regulation 6C-6.0115, the University of South Florida (University/USF) has established the following policy regarding religious observances: (http://usfweb2.usf.edu/usfgc/gc_pp/acadaf/gc10-045.htm)

    In the event of an emergency, it may be necessary for USF to suspend normal operations. During this time, USF may opt to continue delivery of instruction through methods that include but are not limited to: Blackboard, Elluminate, Skype, and email messaging and/or an alternate schedule. It’s the responsibility of the student to monitor Blackboard site for each class for course specific communication, and the main USF, College, and department websites, emails, and MoBull messages for important general information.

  37. Policy on Make-up Work:
  38. Program This Course Supports: Master's Program
  39. Course Concurrence Information: None


- if you have questions about any of these fields, please contact chinescobb@grad.usf.edu or joe@grad.usf.edu.